Aplidine | |
---|---|
(S)-N-((R)-1-(((3S,6R,7S,10R,11S,15S,17S,20S,25aS)-10-((S)-sec-butyl)-11-hydroxy-20-isobutyl-15-isopropyl-3-(4-methoxybenzyl)-2,6,17-trimethyl-1,4,8,13,16,18,21-heptaoxodocosahydro-1H-pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosin-7-yl)amino)-4-methyl-1-oxopentan-2-yl)-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide |
|
Other names
Aplidin; Dihydrodidemnin B; Plitidepsin |
|
Identifiers | |
CAS number | 137219-37-5 |
ChemSpider | 26001665 |
Jmol-3D images | Image 1 |
|
|
|
|
Properties | |
Molecular formula | C57H87N7O15 |
Molar mass | 1110.34 g mol−1 |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
Infobox references |
Aplidine, also known as dihydrodidemnin B, is a chemical compound extracted from the ascidian Aplidium albicans.[1] It is currently undergoing clinical trial testing. It is a member of the class of compounds known as didemnins.
Aplidine is a cyclic depsipeptide, meaning it is a cyclic peptide in which there is one or more ester bond in place of one or more of a peptide bond. Its chemical structure is very close to that of didemnin B, the only difference being that the lactate residue in didemnin B is present in the oxidized pyruvate version.
Like all didemnin compounds, it exhibits antitumor, antiviral and immunosuppressive activities. It shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers.[2][3] As of 2007, it was undergoing multicenter phase II clinical trials.[3] In July 2003, aplidine was granted orphan drug status by the European Medicines Agency for treating acute lymphoblastic leukemia.[4]